EPIX and Bracco settle Multihance patent feud:
This article was originally published in Clinica
EPIX Medical and the Italian company Bracco have settled their legal dispute over EPIX's European patents on MRI contrast imaging agents. Cambridge, Massachusetts-based EPIX has granted Bracco a worldwide licence to the patents - owned by the Massachusetts General Hospital and exclusively licensed to EPIX - in return for a $10 million advance payment. Bracco has also agreed to withdraw its oppositions to the corresponding patent applications in Japan. The deal permits Bracco to market its Multihance MRI contrast agent for liver and central nervous system imaging in Europe and the US, though the product is awaiting US marketing clearance.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.